AUG 21, 2022 10:00 AM PDT

Eczema Drug Helps Increase Covid-19 Survival Rates, Clinical Study Suggests

Credit: Pixabay

In a recent study published in Open Forum Infectious Diseases, a clinical study led by the University of Virginia (UVA) Health System found that the drug, dupilumab, was successful in increasing Covid-19 survival rates in a 60-day randomized trial involving 40 ventilator-free patients. What’s remarkable about this study is dupilumab was initially designed to treat eczema and asthma, and 90% of the patients receiving dupilumab survived after 60-day trial.

"Our clinical trial suggests that treatment with the anti-allergy medicine dupilumab may decrease deaths due to COVID-19. UVA is the first to test this novel and promising approach to COVID-19 treatment, which also proved safe in this small study -- as we had expected, as dupilumab has proven safe and effective as an allergy medicine," said Jennifer Sasson, MD, of the University of Virginia School of Medicine's Division of Infectious Diseases and International Health, and lead author of the study. "A large multi-institution study to validate these preliminary results is being designed. If successful, this multi-site trial will open a new window to treatment of COVID-19 and potentially other viral pneumonias."

Sasson and her colleagues gained inspiration to conduct the trial after discovering that Covid-19 patients were at a much greater risk of requiring a ventilator if their blood contained high levels of interleukin-13 (IL-13), which is a driver of inflammation within the body. Dupilumab functions by blocking the inflammatory effects of IL-13.

The study was conducted by administering either dupilumab or a placebo to 40 patients exhibiting moderate to severe Covid-19 symptoms in a double-blinded trial, meaning both the doctors and patients were unaware who was receiving either dose. While both groups saw no change in survival rates after 28 days, by day 60 there were two deaths among the patients who received dupilumab while there were five deaths for the placebo patients.

While dupilumab should not be considered a “magic bullet” in the fight against Covid-19, the UVA researchers noted that this treatment could be useful for appropriate patients and are encouraging larger trials to better understand the possible benefits of this treatment.

"We are indebted to the patients at UVA who consented to participate in this study, without even knowing if they would receive the medicine or placebo, as they are the ones who have advanced our understanding of the pandemic," Sasson said.

Sources: Open Forum Infectious Diseases, National Library of Medicine

As always, keep doing science & keep looking up!

About the Author
MS in Geological Sciences
Laurence Tognetti is a six-year USAF Veteran who earned both a BSc and MSc from the School of Earth and Space Exploration at Arizona State University. Laurence is extremely passionate about outer space and science communication, and is the author of “Outer Solar System Moons: Your Personal 3D Journey”.
You May Also Like
OCT 05, 2022
Health & Medicine
Emergency Contraception Pills are Significantly Less Effective in People Who Are Overweight
OCT 05, 2022
Emergency Contraception Pills are Significantly Less Effective in People Who Are Overweight
Emergency contraception pills can be used to prevent pregnancy within 72 hours of having unprotected sex. When taken as ...
OCT 24, 2022
Clinical & Molecular DX
A Promising Biomarker for Osteoarthritis Has Been Found
OCT 24, 2022
A Promising Biomarker for Osteoarthritis Has Been Found
Osteoarthritis, the most common form of arthritis, is difficult to diagnose early. Osteoarthritis affects over 32 millio ...
NOV 02, 2022
Cannabis Sciences
Lower Income Charter High School Graduates Have Lower Rates of Substance Abuse
NOV 02, 2022
Lower Income Charter High School Graduates Have Lower Rates of Substance Abuse
UCLA researchers conducted an 8-year study of roughly 1,300 low-income Los Angeles teens and found that students who att ...
NOV 15, 2022
Drug Discovery & Development
Lousy Solutions for Lousy Problems: The New Arms Race with Human Lice
NOV 15, 2022
Lousy Solutions for Lousy Problems: The New Arms Race with Human Lice
In the 1980s and 90s, our marvelous neurotoxic treatments for lice began to fail. New reports of reduced efficacy sugges ...
NOV 16, 2022
Drug Discovery & Development
Flavonoid Delivery Using Nanoparticles Currently On Route
NOV 16, 2022
Flavonoid Delivery Using Nanoparticles Currently On Route
In their article, Dewanjee et al. explains how the use of nanoparticles is a novel solution that can specifically addres ...
NOV 30, 2022
Neuroscience
Study Shows a High Rate of Negative Effects of Ayahuasca
NOV 30, 2022
Study Shows a High Rate of Negative Effects of Ayahuasca
A new study published in PLOS Global Public Health found a high rate of adverse physical and psychological effects from ...
Loading Comments...